piracetam has been researched along with Injury, Ischemia-Reperfusion in 8 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study shows that systemic piracetam treatment provides protection against ischemia-reperfusion injury in musculocutaneous flaps and can offer a simple and inexpensive alternative to the preconditioning technique." | 8.02 | Comparison of Ischemic Preconditioning and Systemic Piracetam for Prevention of Ischemia-Reperfusion Injury in Musculocutaneous Flaps. ( Arslan, H; Aydın, Ö; Aydın, Y; Balcı Ekmekçi, Ö; Demiröz, A; Derebaşınlıoğlu, H; Ekmekçi, H; Ercan, A, 2021) |
| "The purpose of this study is to explore the neuroprotection mechanism of levetiracetam (LEV) with acute focal cerebral ischemia-reperfusion (I/P) mouse." | 7.83 | Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion. ( Bao, H; Hao, J; Li, G; Li, Y; Wang, X; Xu, X; Zhang, Y; Zuo, L, 2016) |
| "The present study investigates the potential of Piracetam and Vinpocetine (nootropic drugs, known to possess neuroprotective properties) in preventing hypoxia-reoxygenation induced oxidative stress in primary hippocampal cell culture." | 7.77 | Preventive effect of piracetam and vinpocetine on hypoxia-reoxygenation induced injury in primary hippocampal culture. ( Ilavzhagan, G; Muthuraju, S; Prasad, D; Sharma, AK; Singh, SB; Solanki, P, 2011) |
| "Flap necrosis was measured on the day 7 in all groups." | 5.37 | Effect of systemic piracetam treatment on flap survival and vascular endothelial growth factor expression after ischemia-reperfusion injury. ( Ayhan, S; Ergun, H; Findikcioglu, K; Tuncer, I; Tuncer, S, 2011) |
| " This study shows that systemic piracetam treatment provides protection against ischemia-reperfusion injury in musculocutaneous flaps and can offer a simple and inexpensive alternative to the preconditioning technique." | 4.02 | Comparison of Ischemic Preconditioning and Systemic Piracetam for Prevention of Ischemia-Reperfusion Injury in Musculocutaneous Flaps. ( Arslan, H; Aydın, Ö; Aydın, Y; Balcı Ekmekçi, Ö; Demiröz, A; Derebaşınlıoğlu, H; Ekmekçi, H; Ercan, A, 2021) |
| "The purpose of this study is to explore the neuroprotection mechanism of levetiracetam (LEV) with acute focal cerebral ischemia-reperfusion (I/P) mouse." | 3.83 | Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion. ( Bao, H; Hao, J; Li, G; Li, Y; Wang, X; Xu, X; Zhang, Y; Zuo, L, 2016) |
| "The present study investigates the potential of Piracetam and Vinpocetine (nootropic drugs, known to possess neuroprotective properties) in preventing hypoxia-reoxygenation induced oxidative stress in primary hippocampal cell culture." | 3.77 | Preventive effect of piracetam and vinpocetine on hypoxia-reoxygenation induced injury in primary hippocampal culture. ( Ilavzhagan, G; Muthuraju, S; Prasad, D; Sharma, AK; Singh, SB; Solanki, P, 2011) |
| "Perinatal arterial stroke is the most frequent form of cerebral infarction in children." | 1.46 | Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model. ( Auvin, S; Baud, O; Bonnin, P; Charriaut-Marlangue, C; Dupuis, N; Enderlin, J; Leger, PL; Morin, L; Perrotte, G, 2017) |
| "Piracetam treatment improved neurological and histopathological alterations, reduced water content and infarct size, but failed to restore/prevent the impaired endogenous defense functions significantly." | 1.39 | Amelioration of cognitive, motor and endogenous defense functions with silymarin, piracetam and protocatechuic acid in the cerebral global ischemic rat model. ( Bafna, PA; Muley, MM; Naik, SR; Patil, RR; Thakare, VN, 2013) |
| "Flap necrosis was measured on the day 7 in all groups." | 1.37 | Effect of systemic piracetam treatment on flap survival and vascular endothelial growth factor expression after ischemia-reperfusion injury. ( Ayhan, S; Ergun, H; Findikcioglu, K; Tuncer, I; Tuncer, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Demiröz, A | 1 |
| Derebaşınlıoğlu, H | 1 |
| Ercan, A | 1 |
| Arslan, H | 1 |
| Aydın, Ö | 1 |
| Ekmekçi, H | 1 |
| Balcı Ekmekçi, Ö | 1 |
| Aydın, Y | 1 |
| Muley, MM | 1 |
| Thakare, VN | 1 |
| Patil, RR | 1 |
| Bafna, PA | 1 |
| Naik, SR | 1 |
| Zhang, Y | 1 |
| Li, Y | 1 |
| Zuo, L | 1 |
| Bao, H | 1 |
| Xu, X | 1 |
| Hao, J | 1 |
| Wang, X | 1 |
| Li, G | 1 |
| Tuglu, D | 1 |
| Yuvanc, E | 1 |
| Ozan, T | 1 |
| Bal, F | 1 |
| Yilmaz, E | 1 |
| Atasoy, P | 1 |
| Kisa, U | 1 |
| Batislam, E | 1 |
| Morin, L | 1 |
| Enderlin, J | 1 |
| Leger, PL | 1 |
| Perrotte, G | 1 |
| Bonnin, P | 1 |
| Dupuis, N | 1 |
| Baud, O | 1 |
| Charriaut-Marlangue, C | 1 |
| Auvin, S | 1 |
| Kalkan, E | 1 |
| Keskin, F | 1 |
| Kaya, B | 1 |
| Esen, H | 1 |
| Tosun, M | 1 |
| Kalkan, SS | 1 |
| Erdi, F | 1 |
| Unlü, A | 1 |
| Avunduk, MC | 1 |
| Cicek, O | 1 |
| Solanki, P | 1 |
| Prasad, D | 1 |
| Muthuraju, S | 1 |
| Sharma, AK | 1 |
| Singh, SB | 1 |
| Ilavzhagan, G | 1 |
| Tuncer, S | 1 |
| Ayhan, S | 1 |
| Findikcioglu, K | 1 |
| Ergun, H | 1 |
| Tuncer, I | 1 |
8 other studies available for piracetam and Injury, Ischemia-Reperfusion
| Article | Year |
|---|---|
Comparison of Ischemic Preconditioning and Systemic Piracetam for Prevention of Ischemia-Reperfusion Injury in Musculocutaneous Flaps.
Topics: Animals; Ischemic Preconditioning; Myocutaneous Flap; Piracetam; Rats; Rats, Sprague-Dawley; Reperfu | 2021 |
Amelioration of cognitive, motor and endogenous defense functions with silymarin, piracetam and protocatechuic acid in the cerebral global ischemic rat model.
Topics: Analysis of Variance; Animals; Brain Ischemia; Catalase; Cognition; Glutathione; Histological Techni | 2013 |
Levetiracetam Prevents Perforin Mediated Neuronal Injury Induced by Acute Cerebral Ischemia Reperfusion.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Female; Levetiracetam; Male; Mice, Inbred C57BL; Mice, | 2016 |
Protective effects of udenafil citrate, piracetam and dexmedetomidine treatment on testicular torsion/detorsion-induced ischaemia/reperfusion injury in rats.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Male; Piracetam; Protective Agents; Pyrimidines; R | 2016 |
Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model.
Topics: Animals; Animals, Newborn; Anticonvulsants; Brain; Brain Ischemia; Disease Models, Animal; Epilepsy; | 2017 |
Effects of iloprost and piracetam in spinal cord ischemia-reperfusion injury in the rabbit.
Topics: Animals; Antioxidants; Disease Models, Animal; Iloprost; Male; Piracetam; Rabbits; Reperfusion Injur | 2011 |
Preventive effect of piracetam and vinpocetine on hypoxia-reoxygenation induced injury in primary hippocampal culture.
Topics: Acetylcholinesterase; Animals; Antioxidants; Hippocampus; Hypoxia; In Vitro Techniques; L-Lactate De | 2011 |
Effect of systemic piracetam treatment on flap survival and vascular endothelial growth factor expression after ischemia-reperfusion injury.
Topics: Animals; Graft Survival; Immunohistochemistry; Laser-Doppler Flowmetry; Male; Models, Animal; Necros | 2011 |